RAPT Therapeutics Inc

RAPT Therapeutics — Investor Presentation (March 2023)

28 slides from RAPT Therapeutics's investor presentation, Mar 14, 2023

  1. Slide 1: Transforming the Treatment of Inflammation and Cancer

    Transforming the Treatment of Inflammation and Cancer Corporate Presentation March 2023 Exhibit 99.2

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "we," or "us") research and clinical development pl

  3. Slide 3: Oral Drugs Targeting Critical Immune Drivers of Disease

    DISCOVERY Oral Drugs Targeting Critical Immune Drivers of Disease RPT193 (Inflammation): Oral agent targeting inflammatory Th2 cells Phase 1b in AD: efficacy on all key exploratory endpoints with excellent safety and tolerability Phase 2b in AD ongoing, data expected mid 2024 Plan to initiate Phase

  4. Slide 4: Proprietary Drug Discovery and Development Engine

    Proprietary Drug Discovery and Development Engine R Drug discovery Clinical development Rapid Interrogating clinically-relevant big datasets to identify targets and biomarkers Driven by data to improve chances of clinical success Critical immune drivers of cancer and inflammation A Analytics P Patie

  5. Slide 5: RPT193: CCR4 Antagonist for Inflammatory Diseases

    RPT193: CCR4 Antagonist for Inflammatory Diseases

  6. Slide 6: RPT193: Oral Th2 Inhibitor for Inflammatory Diseases

    RPT193: Oral Th2 Inhibitor for Inflammatory Diseases Highly potent and selective once-daily oral CCR4 antagonist designed to safely reduce Th2-inflammation in a broad range of allergic disorders Clear benefit on signs and symptoms in Phase 1b in moderate-to-severe atopic dermatitis Favorable safety

  7. Slide 7: RPT193 Targets Th2 Cells: Key Drivers of Inflammation

    RPT193 Targets Th2 Cells: Key Drivers of Inflammation in Atopic Dermatitis, Asthma and Other Diseases Epithelial Barrier Surface CCR4 Th2 IL-5 IL-4 IL-13 Inflammation Thickening Itch Signaling via CCR4 regulates Th2 cell migration into inflamed tissues and enhances cytokine secretion Cytokines Aller

  8. Slide 8: Phase 1b Trial Explored RPT193 Activity in Atopic Dermatitis

    Enrolled 31 patients into a double-blind, randomized trial with 2:1 allocation of RPT193 to placebo Monotherapy study: steroid and immunosuppressant washout period; rescue steroids not permitted through Day 43 Not powered for any specific endpoint Exploratory endpoints include: EASI, Pruritus Numeri

  9. Slide 9: Phase 1b Baseline Demographics and Disease Characteristics

    Phase 1b Baseline Demographics and Disease Characteristics Placebo RPT193 N 10 21 Age, Mean (Range) 35.8 (22-64) 41.0 (19-63) Female, n (%) 4 (40.0%) 12 (57.1%) Baseline Characteristics EASI, Mean (Range) 21.07 (13.6-45.5) 18.49 (12-30) BSA, Mean (Range) 24.5 (10-61) 23.3 (11-55) vIGA 3, n (%) 8 (80

  10. Slide 10: RPT193 Differentiated from Placebo for EASI and EASI-50

    RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29 with Further Improvement at Day 43 % Improvement in EASI Proportion of EASI-50 19.3% 43.6% 32.9% 41.9% Follow-up Treatment Follow-up Treatment *p < 0.05 * *

  11. Slide 11: RPT193 Differentiated from Placebo on EASI-75 and vIGA 0/1

    RPT193 Differentiated from Placebo on EASI-75, 90 and vIGA 0/1 at Day 43 *p < 0.05 * 28.6% 9.5% 14.3% 61.9% 20% 0% 0% 0% ** 36.4% 9.1% 27.3% 63.6% 0% 0% 0% 0% (N=8) (N=11) **p < 0.01 EASI ≥ 12 ITT EASI ≥ 16 Subgroup Similar efficacy between ITT and EASI ≥ 16 Subgroup

  12. Slide 12: RPT193 Improved AD-Associated Gene Signatures in the Skin

    RPT193 Demonstrated Significant Improvement in AD-Associated Gene Signatures in the Skin MADAD: Meta-Analysis Derived Atopic Dermatitis score ***(p<0.001) Changes in the Lesional AD Transcriptome Mean % Improvement in MADAD Transcriptome *** -4% 52% % Improvement 40 20 0 PbO RPT193 NL Day1 Day29 NL

  13. Slide 13: RPT193 Demonstrated Improvement in Itch and Sleep

    RPT193 Demonstrated Improvement in Itch and Sleep Proportion of NRS-4† 22.2% 45.0% †At least a 4-point improvement among patients with a baseline pruritus NRS ≥4 * % Change in Patient Oriented SCORAD (Sleep Loss + Pruritus) *p < 0.05

  14. Slide 14: RPT193 6-Week Efficacy vs. Other Drugs at 12-16 Weeks

    RPT193 6-Week Efficacy vs. Other Drugs at 12-16 Weeks* RPT193 RPT193 400 mg Biologics Orals Dupilumab Ph3 (300 mg q2wk) Lebrikizumab Ph2 (250 mg q2wk) Tralokinumab Ph3 (300 mg q2wk) Abrocitinib Ph3 (200 mg) Baricitinib Ph3 (2 mg) Etrasimod Ph2 (2 mg) Upadicitinib Ph2,3 (15 mg) % EASI improvement EAS

  15. Slide 15: RPT193 Phase 1b Safety

    RPT193 Phase 1b Safety No SAEs reported All AEs reported were mild or moderate in intensity No clinically significant safety laboratory abnormalities observed Overall safety profile suggests a well-tolerated oral drug that should not require laboratory safety monitoring

  16. Slide 16: Ongoing Dose-Finding Phase 2b Monotherapy Trial in Atopic Dermatitis

    Ongoing Dose-Finding Phase 2b Monotherapy Trial in Patients with Moderate-to-Severe Atopic Dermatitis 169 Obtain Informed Consent ≥12-month history of AD 18-75 years of age BMI ≥18 BSA ≥10% EASI ≥16 vIGA ≥3 Screening (Up to 5 weeks) Day -35 -1 RPT193 400 mg once daily RPT193 200 mg once daily RPT193

  17. Slide 17: Proposed Phase 2a Asthma Trial Design

    Proposed Phase 2a Asthma Trial Design CONFIDENTIAL Goal enrollment: ~100 patients, ~50 per arm Primary Endpoint: “Loss of Asthma Control” Secondary Endpoint: ACQ-5, FEV1, etc. Obtain Informed Consent Moderate-to-severe Type 2 asthmatics Screening (Up to 6 weeks) Day -42 -1 RPT193 400 mg once daily P

  18. Slide 18: RPT193 Commercial Vision: Building a Global Blockbuster

    RPT193 Commercial Vision: Building a Global Blockbuster Value Statement Positioning As the first-choice systemic therapy Sources: GlobalData: Atopic Dermatitis Global Drug Forecast and Market Analysis to 2030 | March 2022 * Decision Resources Guide; EU, US, and Japan market Simple, once-daily oral p

  19. Slide 19: Potential "Pipeline in a Product"

    Potential “Pipeline in a Product” Dermatology Respiratory Chronic Rhinosinusitis Allergy Eosinophilic Esophagitis Prurigo Nodularis Bullous Pemphigoid Alopecia Areata Asthma COPD (Th2 high) IPF Atopic Dermatitis Allergic Rhinitis Th2-Driven Inflammatory Diseases Chronic Urticaria

  20. Slide 20: RPT193 Program Summary

    RPT193 Program Summary Oral selective Th2 inhibitor with clear benefit on signs and symptoms in AD Well tolerated with favorable safety Profile supports competitive positioning ahead of injectables and oral JAKs Massive commercial opportunity in AD, asthma and other Th2 indications 16-week Phase 2b

  21. Slide 21: FLX475: CCR4 Antagonist for Oncology

    FLX475: CCR4 Antagonist for Oncology

  22. Slide 22: Treg Are Key Targets in the Tumor Microenvironment

    Treg Are Key Targets in the Tumor Microenvironment (TME) Correlate with poor prognosis across most cancers Mechanism for immune evasion by viruses and tumors Barrier to checkpoint inhibitor efficacy Challenge: selective inhibition of Treg in the TME Depleting antibodies targeting CD25, CCR4, etc. do

  23. Slide 23: FLX475: Tumor Specific Treg Inhibitor in Phase 2

    FLX475: Tumor Specific Treg Inhibitor in Phase 2 Chemically distinct potent and selective CCR4 small molecule antagonist Selectively blocks tumor Treg while sparing normal tissues and beneficial cells Potential for superior safety and efficacy compared to depleting antibodies US patent coverage thro

  24. Slide 24: Identification and Characterization of Charged Tumors

    Identification and Characterization of Charged Tumors “Charged” tumors: high CCR4 ligands, Treg and CD8 T cells Potential for both monotherapy and combination activity Include cancers with high unmet need and large markets Phase 2 trial expansions focused on charged cancers Data from in-house analys

  25. Slide 25: Encouraging Monotherapy and Combination Efficacy

    Encouraging Monotherapy and Combination Efficacy Pembro Mono Pembro+TIGIT Pembro+FLX475 18%† 31% (4/13)^ 38% (3/8) ORR Comparison in PD-L1+* NSCLC *TPS ≥ 1%; †Keynote-010; ^Niu et al. ESMO 2020 CPI-Naïve NSCLC (Combo) EBV+ NK/T Lymphoma (Monotherapy) 4 of 6 responses to FLX475 monotherapy including

  26. Slide 26: FLX475 Program Summary

    FLX475 Program Summary Highly selective tumor Treg inhibitor differentiated from biologics Encouraging early efficacy as monotherapy and in combination with pembrolizumab Favorable safety and convenient oral dosing support broad combinability Enrolling Stage 2 expansions in 3 indications including C

  27. Slide 27: Key Takeaways and Upcoming Milestones

    Key Takeaways and Upcoming Milestones RPT193: safe oral agent designed for a broad range of inflammatory diseases, in a definitive Phase 2b study in AD FLX475: highly selective tumor Treg inhibitor in multiple Phase 2 expansions as monotherapy and in combination with pembrolizumab Planned Key Milest

  28. Slide 28: Thank You

    Thank You

RAPT Therapeutics — Investor Presentation (March 2023) on 6ix